Scholarlink

<p>Although renin-angiotensin system (RAS) inhibitors and calcium channel blockers are widely used to treat hypertension in Japan, &lt;10% of patients use thiazides. This study aimed to evaluate differences in the efficacy and safety of sacubitril/valsartan and thiazide diuretics. Patients with poor blood pressure (BP) control, despite combination treatment with RAS inhibitors and calcium channel blockers, were included in the study. Patients treated with thiazides (THZ group, <i>n</i> = 306) and those who switched from RAS inhibitors to sacubitril/valsartan (SacVal group, <i>n</i> = 433) were compared. Propensity score analysis with inverse probability weighting was performed. A significantly higher target BP achievement rate was observed in the SacVal group than in the THZ group (4 months, 37% vs. 26%, <i>p</i> &lt; 0.001). In a general linear mixed model, significant decreases in office and home BP were observed in both groups (<i>p</i> &lt; 0.001); however, no significant interaction effects were observed between the drug type and time course. Discontinuation of the treatment by adverse events was significantly more frequent in THZ group (10%) than in SacVal group (3%), with a hazard ratio [95% confidence interval] of 3.47 [1.78, 6.76] (<i>p</i> &lt; 0.001). In the model using the propensity score, compared with THZ group, significantly lower levels of office and home systolic BP, uric acid, glycated hemoglobin A<sub>1c</sub>, and higher levels of eGFR were observed in SacVal group (<i>p</i> = 0.04, 0.002, &lt;0.001, 0.01, and 0.02, respectively). In conclusion, comparable BP reduction and positive effects on metabolic parameters were observed with sacubitril/valsartan treatment, with better treatment tolerability than thiazide diuretics.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparison between sacubitril/valsartan and thiazide diuretics among patients with uncontrolled hypertension in Japan

  • 期刊论文

  • 发表日期：

    2025年5月19日

查看全文
  • Kazuo Kobayashi,
  • Mari Sotozawa,
  • Keiichi Chin,
  • Hideo Shimura,
  • Kyoji Chiba,
  • Shun Ito,
  • Toshinao Tsuge,
  • Hiroyuki Sakai,
  • Takayuki Furuki,
  • Atsushi Matsuzaki,
  • Shinichi Nakajima,
  • Nobukazu Takada,
  • Hareaki Yamamoto,
  • Hiroshi Takeda,
  • Hiromichi Wakui,
  • Takamasa Iwasawa,
  • Togo Aoyama,
  • Masao Toyoda,
  • Kouichi Tamura,
  • Akira Kanamori

摘要

Although renin-angiotensin system (RAS) inhibitors and calcium channel blockers are widely used to treat hypertension in Japan, <10% of patients use thiazides. This study aimed to evaluate differences in the efficacy and safety of sacubitril/valsartan and thiazide diuretics. Patients with poor blood pressure (BP) control, despite combination treatment with RAS inhibitors and calcium channel blockers, were included in the study. Patients treated with thiazides (THZ group, n = 306) and those who switched from RAS inhibitors to sacubitril/valsartan (SacVal group, n = 433) were compared. Propensity score analysis with inverse probability weighting was performed. A significantly higher target BP achievement rate was observed in the SacVal group than in the THZ group (4 months, 37% vs. 26%, p < 0.001). In a general linear mixed model, significant decreases in office and home BP were observed in both groups (p < 0.001); however, no significant interaction effects were observed between the drug type and time course. Discontinuation of the treatment by adverse events was significantly more frequent in THZ group (10%) than in SacVal group (3%), with a hazard ratio [95% confidence interval] of 3.47 [1.78, 6.76] (p < 0.001). In the model using the propensity score, compared with THZ group, significantly lower levels of office and home systolic BP, uric acid, glycated hemoglobin A1c, and higher levels of eGFR were observed in SacVal group (p = 0.04, 0.002, <0.001, 0.01, and 0.02, respectively). In conclusion, comparable BP reduction and positive effects on metabolic parameters were observed with sacubitril/valsartan treatment, with better treatment tolerability than thiazide diuretics.